Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens ...

SCYNEXIS will receive a milestone payment from Hansoh upon commercialization as well as royalties of approximately 10% on China sales. "The lifting of the clinical hold for ibrexafungerp was an ...

Explore the complete guide to tuberculosis, from bacterial causes and early warning signs to modern treatment approaches and ...

Antibiotic resistance is a pressing issue within the realm of global health, posing significant challenges, particularly in ...

Prof. Thomas Efferth, Chief Editor of Phytomedicine and a pioneering figure in molecular pharmacology and natural product research, has profoundly shaped ...

Antimicrobial resistance, in which germs like bacteria and fungi no longer respond to medicines, is a rising global threat.

A growing resistance to antibiotics is complicating the treatment of urinary tract infections (UTIs) in Malawi, with new ...

Preventing the development of drug-resistant TB through a good control program based on directly observed treatment, short-course, is of paramount importance. Established multidrug-resistant (MDR ...

MRSA: Methicillin-resistant Staphylococcus aureus; VAP: Ventilator-associated pneumonia. Adapted from the American Thoracic Society/Infectious Disease Society of America guidelines [3].

The rapid rise of multidrug-resistant (MDR) bacteria makes treating bacterial infections increasingly difficult, and the widespread use of antibiotics in agricultural, clinical, and residential ...

Serious bloodstream infections are already difficult to manage in patients with multi-drug resistant bacteria, and further resistance only makes these infections less likely to respond to "reserve ...